item management s discussion and analysis of financial condition and results of operations results of operations the following discussion and analysis should be read in conjunction with the company s financial statements and related notes appearing elsewhere in this report 
consolidated net income for was  compared to net losses of million in  on a restated basis  and million in the company marked its first profitable year in  which is attributable primarily to continued growth in inovoject r revenues 
earnings per share increased from net losses of in and 
in  on a restated basis  to net income of 
in for the year ended  weighted average shares outstanding were million  up from and million at year end and  respectively 
see liquidity and capital resources 
revenues consolidated revenues in totaled million  representing an increase of over revenues million which was over revenues million 
inovoject r revenues totaled million in compared to million in and million in  representing increases of from to  and from to the revenues include inovoject r lease fees derived from multi year contracts and paid trials in the us and foreign countries  the sale of inovoject r systems to distributors  and the sale of one inovoject r system to a pharmaceutical company for use in the production of human influenza vaccine 
embrex does not expect sales of inovoject r systems for use in the production of vaccines  if any  to be a significant source of future revenue 
at december   embrex had over inovoject r systems installed and operating under lease agreements worldwide  up from systems at december   and at december  additionally  embrex estimates that as of december   it was vaccinating approximately of the billion broiler birds grown in the us in  up from in  and in management anticipates further revenue growth in from existing inovoject r operations in the united states and canada  new inovoject r system leases in other countries  and sales of bursaplex tm product to poultry producers 
however  the rate at which the marketplace will accept the inovoject r technology outside the united states and canada  the timing of approvals of third party vaccines for in ovo use outside the united states and canada  possible variability in us hatchery bird production as a result of recent high grain prices  and possible variability in the demand for us poultry and poultry products outside the us  will impact the pace of revenue growth  if any  and the sustaining of profitability from the installation and operational throughputs of inovoject r systems 
sales of the company s proprietary viral neutralizing factor product vnf for inclusion in gumboro disease vaccines were the principal source of product revenues  which generated million   and  in   and  respectively 
cost of product sales and inovoject r revenues cost of revenues as a percentage of revenues decreased from and of total revenues in and  respectively  to of total revenues in the improvement in is primarily attributable to the fact that revenues increased at a rate substantially in excess of the rate of change in the cost of products 
operating expenses operating expenses totaled million in compared to million in  and million in general and administrative g a expenses were million in  up from million in  and from million in the increase was largely due to increased legal expenses associated with the implementation of a shareholder rights plan in march and amendments to the company s articles of incorporation approved at the annual meeting of shareholders in may the increase over was attributable to legal expenses incurred in connection with various patent infringement lawsuits filed  and subsequently settled  by the company during see legal proceedings 
sales and marketing expenses totaled  in compared to  and  in and  respectively 
the increases in and resulted from stepped up international activity  principally in europe  as well as general increases in the company s sales and customer service functions to support market expansion and field support of inovoject r systems 
research and development r d expenses were million in compared to million in and million in the increase in r d expense from to largely reflects an increase in outside contract research  supplies consumption  and inovoject r design and development activity 
the decrease in expense from to is principally attributable to reductions in contract research  lower use of consumable supplies  and a reduction in inovoject r design and development activity 
the company continues to manage its research and development effort to leverage its know how  patent position  market presence and expenditures 
other income and expense interest income totaled   and  in years   and  respectively 
the decrease relative to resulted principally from lower interest rates  while the increase in relative to was a function of higher cash balances 
interest expense totaled million in compared to million  on a restated basis in  and  in in all years  the amount of expense is principally attributable to the company s funding of its growing installed base of inovoject r systems with the use of capital lease financing and in the issuance of convertible debentures 
additionally  interest expense for has been restated to reflect a one time charge associated with recognizing  of interest expense attributable to the difference between the market price of the company s common stock and the conversion price of the debentures issued in see liquidity and capital resources and note to the company s financial statements 
management expects to place a greater emphasis and reliance on the use of internally generated funds to finance the cost of additional inovoject r systems in effect of inflation management expects cost of product sales and inovoject r revenues  operating expenses and capital equipment costs to change in line with periodic inflationary changes in price levels 
management also believes that the company will be able to offset the effect of price level changes by adjusting selling lease prices and effecting operating efficiencies 
consequently  management does not expect changes in price levels to have any material adverse affect on its results of operations 
liquidity and capital resources at december   the company s cash and short term investment balances totaled million compared to million and million at december  and  respectively 
working capital increased from million in to million in primarily due to the exercise of warrants as described below 
during  operating activities generated million in cash  including  million attributable to a net increase in working capital 
within investing activities  inovoject r and equipment purchases required million  while the sale of short term investments  provided an offsetting million 
in addition  financing activities during generated a net million in cash reflecting million from the issuance of equity and debt securities offset by approximately  in net payments on capital lease obligations 
to diversify its sources of external financing  in september the company obtained a million line of credit from a bank in the united kingdom  which will be used to finance the construction of additional inovoject r systems for europe  the middle east and africa 
the line is secured by compensating cash balances on deposit with the bank in an amount equal to the funds loaned 
the company will receive interest on the deposited funds  and will pay interest on the loaned funds at a rate of in excess of the interest it earns 
the terms call for minimum drawdowns of  with repayment of each drawdown over four years 
the company utilized  of this line in in november  the holders of warrants to purchase common stock  originally issued to the managing underwriter of the company s initial public offering  exercised such warrants for  shares at an aggregate exercise price of  also in november  warrants to purchase approximately million shares of common stock at exercise prices ranging from to per share expired 
after giving effect to these events  warrants to purchase a total of  shares of common stock at prices ranging from to  subject to adjustment  remain outstanding 
these outstanding warrants have expiration dates ranging from july  through june  the company had outstanding purchase commitments of approximately million as of december  which were principally related to construction of additional inovoject r systems scheduled for delivery at various times during as well as the production of bursaplex tm 
see subsequent events 
based on its current operations  management believes that its available cash and short term investments  together with cash flow from operations and existing equipment financing lines  will be sufficient to meet its foreseeable cash requirements 
subsequent events on january   the company received us department of agriculture usda approval for in ovo use of the company s viral neutralizing factor based vaccine for ibd in broiler chickens 
the approval is specifically for in ovo as opposed to post hatch administration of the vaccine complex via embrex s inovoject r systems 
trade named bursaplex tm  this new vaccine previously called bda blen is a unique combination of an existing strain of ibd vaccine and embrex s patented viral neutralizing factor vnf licensed from the university of arkansas 
vnf has been shown to render a virulent infectious bursal disease vaccine both safe and effective in broiler chickens  thus allowing its use at or before hatch 
some of the health benefits of this new vnf vaccine complex include single dose efficacy and effective early vaccination in broilers 
infectious bursal disease weakens a chicken s immune system  resulting in poor growth and the potential for contracting other diseases 
the disease is widespread in the united states  northern europe and asia 
forward looking statements information set forth in this annual report on form k contains various forward looking statements within the meeting of section a of the securities act of and section e of the securities exchange act of  which statements represent the company s judgment concerning the future and are subject to risks and uncertainties that could cause the company s actual operating results and financial position to differ materially 
such forward looking statements can be identified by the use of forward looking terminology such as may  will  expect  anticipate  estimate  believe  or continue  or the negative thereof or other variations thereof or comparable terminology 
the company cautions that any such forward looking statements are further qualified by important factors that could cause the company s actual operating results to differ materially from those in the forward looking statements  including without limitation the company s dependence on certain customers  the ability of the company  its manufacturing and marketing partners and others to obtain regulatory approval for products to be delivered in ovo  which are dependent on a number of factors  including the results of trials  the discretion of regulatory officials  and any potential changes in regulations  the company s ability to generate future cash flow from operations  continued demand for the inovoject r system  the risk factors described in exhibit to this report  and other risks detailed from time to time in the company s securities and exchange commission filings  including the company s forms q  k  and k 

